Ask AI
Bispecific Antibodies in MM

CE

APP Perspectives: Managing Toxicities With Bispecific Antibodies in Multiple Myeloma

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: November 07, 2025

Expiration: May 06, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Charise Gleason, MSN, NP-C, AOCNP provides an overview of the key considerations in identifying, preventing, and managing AEs associated with bispecific antibody therapy in MM. The discussion highlights strategies to recognize and mitigate BCMA- and GPRC5D-targeted bispecific antibody–associated AEs including CRS, ICANS, and infections, emphasizing risk assessment, timely intervention, and multidisciplinary coordination to optimize patient safety and treatment outcomes.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Please note that Clinical Care Options plans to measure the educational impact of this activity. Some questions are asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your individual responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

You are treating a patient with teclistamab who completed step-up dosing and is on cycle 6 of standard dosing. The patient presents with a new fever and general fatigue. What potential cause do you suspect?

You are reviewing the unique AE profiles of BCMA- and GPRC5D-targeted bispecific antibody therapies with a patient with relapsed/refractory (R/R) multiple myeloma (MM) and their caregiver. Which of the following AEs is more commonly observed with GPRC5D-targeted therapy compared with BCMA-targeted therapy in MM?

How many people with MM do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting:

In addition to using tocilizumab to treat existing CRS, do you consider prophylactic tocilizumab to prevent CRS in your patients with R/R MM being treated with bispecific antibody therapy?